BR-790 is under clinical development by Shanghai Gefeimu Biomedical Technology and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData, Phase II drugs for Non-Small Cell Lung Cancer have a 39% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how BR-790’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

BR-790 overview

BR-790 is under development for the treatment of advanced solid tumor including non-small cell lung cancer, colorectal cancer, esophageal squamous cell carcinoma, head and neck cancer squamous cell carcinoma. It is administered through oral route as a tablet.

Shanghai Gefeimu Biomedical Technology overview

Shanghai Gefeimu Biomedical Technology (Gefeimu Biomedical) operate in healthcare sector. Gefeimu Biomedical is headquartered in Shanghai, China.

For a complete picture of BR-790’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.